Active surveillance (AS) is currently accepted as a good management option for men with low-risk prostate cancer (PCa). Moreover, given the grade migration following the 2005 International Society of Urologic Pathology consensus conference, AS may be appropriate for men presenting with favorable intermediate-risk PCa. Three contemporary experiences of AS for men with intermediate-risk features suggest that although these men are at higher risk for radical treatment, most of them are not significantly compromising chances for long-term cure. From the long-term randomized ProtectT trial, 10-year outcomes after active monitoring, surgery, or radiotherapy for localized PCa revealed that PCa specific mortality was low irrespective of the treatment assigned, with no significant difference among treatments. Multiparametric magnetic resonance imaging, molecular biomarkers, and new Gleason grading system could enhance diagnostic accuracy and decrease the demerits of current AS protocols. Particularly, uniform recording of the percentage pattern 4 in Gleason 7 cancers will enable better understanding of prognostic risks and consideration of careful expansion of AS to populations with minimal Gleason pattern 4 disease. 
ERSPC의 Rotterdam and Helsinki arms 코호트 연구
Bul 등 CI, confidence interval. *p-values were calculated with the use of a log-rank test of the null hypothesis of no difference in effectiveness across the 3 treatments. The planned adjusted analysis was not possible owing to the low number of events. † Deaths due to prostate cancer were defined as deaths that were definitely or probably due to prostate cancer or its treatment, as determined by the independent cause-of-death evaluation committee. ‡ Disease progression was defined as death due to prostate cancer or its treatment; evidence of metastatic disease; long-term androgen-deprivation therapy; clinical T3 or T4 disease; and ureteric obstruction, rectal fistula, or the need for a permanent catheter when these are not considered to be a complication of treatment. 
